News articles about Conatus Pharmaceuticals (NASDAQ:CNAT) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Conatus Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.0445490030165 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Conatus Pharmaceuticals traded down $0.13, reaching $4.05, during midday trading on Friday, MarketBeat reports. The company had a trading volume of 130,575 shares, compared to its average volume of 244,170. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.35 and a quick ratio of 2.35. The firm has a market cap of $126.00 million, a P/E ratio of -6.64 and a beta of 1.23. Conatus Pharmaceuticals has a 1-year low of $3.22 and a 1-year high of $7.95.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The business had revenue of $8.77 million during the quarter, compared to analyst estimates of $9.06 million. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. sell-side analysts expect that Conatus Pharmaceuticals will post -0.61 EPS for the current year.
CNAT has been the subject of a number of analyst reports. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, May 3rd. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 4th. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 1st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.50.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: Do closed-end mutual funds pay dividends?
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.